CATT: Role reversal on safety

Setting aside cost, the real medical debate over the CATT study is centered on safety differences seen in the Avastin bevacizumab and Lucentis ranibuzimab arms.

In previous drug safety controversies, including Avandia rosiglitazone from GlaxoSmithKline plc and the COX-2 inhibitors, academic researchers argued that small increases in risk seen in controlled clinical trials and in epidemiological studies should be taken extremely seriously...